A separate phase I clinical trial in metastatic NSCLC re-formulated the GVAX® vaccine by adjuvanting autologous irradiated tumor cells with an allogeneic GM-CSF secreting cell line [156]. This evidence concerns the gene CSF2 and neoplasm.